Kiniksa Pharmaceuticals International EV/EBIT KNSA
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2023.
- Today, Nov 2, 2026
- 65.5×
- 4-year median
- 50.3×
- Against its 4-year history
- 73rd
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 23.6× to 492×
- Peer median
- 58.4×
Kiniksa Pharmaceuticals International's EV/EBIT is 65.5× as of Nov 2, 2026.
That is above its 4-year median of 50.3×, higher than on 73% of days in the last 4 years.
Over that time it ranged from 23.6× in Oct 2023 to 492× in Aug 2025.
The median for 10 large drugmakers of a similar size is 58.4×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 65.5× | 35.0× | 85.9× |
| 2025 | 74.5× | 64.5× | 492× |
| 2024 | n/m a value too high to mean anything | ||
| 2023 | 23.6× | 23.6× | 68.7× |
Against its peers
Companies in Drug Manufacturers - General nearest Kiniksa Pharmaceuticals International's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| KNSAKiniksa Pharmaceuticals International | 65.5× |
| ALKSAlkermes plc. | 71.4× |
| AMRXAmneal Pharmaceuticals | 18.4× |
| LGNDLigand Pharmaceuticals | 58.4× |
| CORTCorcept Therapeutics | n/m |
| PTGXProtagonist Therapeutics | 141× |
| TGTXTG Therapeutics | 68.7× |
| BMRNBiomarin Pharmaceutical | 26.3× |
| INDVIndivior Pharmaceuticals | 8.2× |
| ARQTArcutis Biotherapeutics | 111× |
| LQDALiquidia | 21.3× |
| Peer median | 58.4× |
Where Kiniksa Pharmaceuticals International ranks
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Kiniksa Pharmaceuticals International
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.